(VIANEWS) - The Market ended the session with ARCTICZYMES TECHNO (AZT.OL) jumping 9.16% to kr29.20 on Monday while Oslo Børs Benchmark Index_GI jumped 0.25% to kr1,267.23.
ARCTICZYMES TECHNO's last close was kr26.75, 66.37% under its 52-week high of kr79.55.
About ARCTICZYMES TECHNO
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Earnings Per Share
As for profitability, ARCTICZYMES TECHNO has a trailing twelve months EPS of kr0.34.
PE Ratio
ARCTICZYMES TECHNO has a trailing twelve months price to earnings ratio of 85.88. Meaning, the purchaser of the share is investing kr85.88 for every norwegian krone of annual earnings.
Return on Equity
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.15%.
Volume
Today's last reported volume for ARCTICZYMES TECHNO is 34591 which is 20.74% below its average volume of 43647.
More news about ARCTICZYMES TECHNO (AZT.OL).